Home>Topics>Funds>SPDR S&P International Financial Sector

SPDR S&P International Financial Sector

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 1- IPF says growth hit by competition from payday lenders, banks


    Wed, 25 Feb 2015

    Feb 25 (Reuters) - International Personal Finance Plc said on Wednesday its growth in Eastern Europe slowed in the final weeks of 2014 due to intensifying competition from payday lenders and banks, especially in Poland and the Czech Republic.

  2. Roche's Acquisition of InterMune Comes at Steep Price, but We're Maintaining Our Roche FVE


    Mon, 25 Aug 2014

    of information will be Esbriet's U.S. price--if we assume 25% penetration of the 200,000 patients believed to have IPF in the U.S. and Europe combined, as well as an $80,000 U.S. price, peak sales above $3 billion in 2022 are achievable

  3. Detailed Phase III Results Give Esbriet the Edge Over Competition; Increasing Our FVE to $32


    Mon, 19 May 2014

    Esbriet in more severe patients, which represent about a third of IPF patients, even though it was tested in mild to moderate patients in its trials. Considering the lack of approved therapies for IPF in the United States and the severe unmet need among patients

  4. InterMune Reports Strong 1Q Esbriet Sales; Maintaining Fair Value Estimate


    Fri, 2 May 2014

    milestone for the company will be the presentation of detailed Phase III results from Esbriet and Boehringer Ingelheim's competing IPF treatment, BIBF-1120, at the American Thoracic Society conference in mid-May. Esbriet revenue grew to $30.3 million

  5. Positive Phase III Data from Boehringer Ingelheim, but No Clear Winner in IPF Market


    Fri, 21 Mar 2014

    Preliminary Phase III data from Boehringer Ingelheim’s trials of nintedanib in IPF were presented in abstract form prior to their presentation at the American Thoracic Society conference in May. While the abstracts

  6. InterMune's 2014 Guidance Is Positive, but Key Value Driver Remains Q2 Esbriet Trial Results


    Thu, 9 Jan 2014

    Phase III ASCEND study in idiopathic pulmonary fibrosis, or IPF --which are expected early next quarter and are necessary for ..... reporting the results of its two Phase III trials for BIBF-1120 in IPF in early 2014, which, if positive, could add competition to

  7. We See Major Upside Potential for InterMune's Shares


    Fri, 12 Apr 2013

    treat idiopathic pulmonary fibrosis, or IPF . The disease causes fatal lung scarring ..... trial to support the efficacy of Esbriet in IPF patients. In our view, the FDA requested ..... 000 people in the U.S. suffer from IPF , and there are currently between 50,000

  8. Weak Initial Sales Guidance for Esbriet, but Still Looks Poised for Long-Term Growth


    Mon, 23 Jul 2012

    also weighed on sales growth. However, typically, the sickest patients are prescribed the drug during the initial launch, and we think discontinuations will fall over time as prescriptions reflect the broader mild-to-moderate IPF market.

  9. InterMune is in the Process of Launching Esbriet Abroad; We Expect Sales to Ramp Throughout 2012


    Fri, 27 Apr 2012

    by-country launch timelines in Europe are causing large swings in InterMune's stock, we think the overall outlook for the IPF drug remains positive. We're keeping our fair value estimate intact, and we believe recent volatility presents investors

  10. InterMune's Future Remains Uncertain


    Mon, 24 May 2010

    for lead drug candidate pirfenidone for the treatment of idiopathic pulmonary fibrosis . Considering the debilitating nature of IPF and the fact that pirfenidone did show efficacy in one of its two Phase III trials , we think there is a high chance the drug

« Prev12Next »
Content Partners